Press Releases

Jul 15, 2025, 07:30 ET Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment Combination of oral PL7737 and tirzepatide resulted in additive weight loss effects IND-enabling toxicology program ongoing IND submission planned for 4Q2025; Clinical data expected in 1H2026 PRINCETON, N.J., July 15, 2025 /PRNewswire/ — Palatin Technologies, […]

May 14, 2025, 07:30 ET Significant Progress in Obesity and Ocular Programs Teleconference and Webcast to be held today – May 14, 2025, at 11:00 AM EST CRANBURY, N.J., May 14, 2025 /PRNewswire/ — Palatin Technologies, Inc. (OTC PINK: PTNT), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the

May 09, 2025, 07:30 ET Findings highlight PL9654 and PL9655’s potential to treat diabetic retinopathy through inflammation resolution, vascular stabilization, and neuroprotection PL9654 and PL9655 down-regulate inflammatory pathways, suppress angiogenesis, and preserve retinal structure and function Topical and systemic administration options enable potential for earlier intervention than current therapies Results support the continued development of

May 08, 2025, 22:19 ET Company Transitioned onto the OTC Pink CRANBURY, N.J., May 8, 2025 /PRNewswire/ — Palatin Technologies, Inc. (OTC PINK: PTNT) (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of a reduced previously announced

May 08, 2025, 16:39 ET Updated Phase 3 analysis highlights PL9643 as a potential first-in-class treatment achieving full symptom resolution. Responder analyses demonstrate statistically significant symptom resolution across multiple endpoints in PL9643-treated patients compared to placebo. 6 of 13 symptom endpoints reached statistical significance (p<0.05). This level of symptom clearing has not been demonstrated by any

May 07, 2025, 20:26 ET The Company Intends to Request a Review of the Delisting Determination CRANBURY, N.J., May 7, 2025 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines targeting the melanocortin receptor system, today announced that it has received a notice from the NYSE American LLC (“NYSE

May 07, 2025, 08:15 ET Funding Supports Advancement of Obesity Program and Strategic Business Development Initiatives Advancement of novel next-generation MC4R long-acting peptides and oral small molecules IND applications planned for Q4 2025; clinical data expected H1 2026 Phase 1 SAD/MAD studies to include patients with hypothalamic obesity Ocular asset collaborations expected in Q2 and Q3

May 07, 2025, 08:00 ET $11.5 Million Upfront with up to an Additional $11.5 Million Upon the Cash Exercise of the Milestone Related Warrants CRANBURY, N.J., May 7, 2025 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of

May 05, 2025, 07:30 ET Topical melanocortin therapy shows promise for treating glaucoma PL9588 lowers intraocular pressure (IOP) by increasing aqueous outflow Demonstrates neuroprotection independent of IOP reduction Supports continued development of PL9588 as a novel, dual-action glaucoma therapy CRANBURY, N.J., May 5, 2025 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company advancing

Apr 29, 2025, 07:30 ET Updated Phase 3 analyses position PL9643 as a potential first-in-class therapy achieving full symptom resolution in dry eye disease. Responder analyses demonstrated statistically significant symptom clearing (resolution) across multiple endpoints in patients treated with PL9643, compared to placebo. Six of 13 symptom endpoints showed a significantly higher percentage of patients